DermIQ-VLM: Dermatological Vision–Language Model

• DermIQ-VLM is a dermatology-specific vision–language model that integrates multi-stage optimization and chain-of-thought reasoning to mimic expert diagnostic workflows.
• It leverages Qwen2-VL backbones with LoRA adaptations and 4-bit quantization, enabling low-resource fine-tuning and notable gains in disease detection performance.
• The model employs sequential modules for concept perception and explainable reasoning, offering auditable rationales that improve clinical decision-making.

to=shell 彩神争霸能json {"command":["bash","-lc","python - <<'PY'\nimport urllib.request\nurl='https://export.arxiv.org/api/query?search_query=id:([2508.06624](/papers/2508.06624))&start=0&max_results=1'\ntry:\n data=urllib.request.urlopen(url,timeout=20).read(200)\n print(data.decode('utf-8','ignore'))\nexcept Exception as e:\n print('ERR',e)\nPY"]} to=shell 大发快三计划 天天爱彩票 code python - <<'PY' import urllib.request url='https://export.arxiv.org/api/query?search_query=id:([2508.06624](/papers/2508.06624))&start=0&max_results=1' try: data=urllib.request.urlopen(url,timeout=20).read(200) print(data.decode('utf-8','ignore')) except Exception as e: print('ERR',e) PY

to=shell պարզ text code echo test

to=shell պարզ text code python - <<'PY' print('hello') PY

DermIQ-VLM denotes a dermatology-specialized vision–LLM developed under low-resource conditions on Qwen2-VL backbones, and, in closely related work, a next-generation design target derived from the explainable diagnostic framework VL-MedGuide. Across these two 2025 formulations, the term is associated with dermatologist-like stepwise reasoning, multi-stage optimization, and an explicit attempt to couple disease recognition with auditable rationales rather than purely visual black-box prediction (Yu et al., 8 Aug 2025, Swapnil et al., 23 Sep 2025).

1. Emergence of the DermIQ-VLM concept

The immediate conceptual precursor to DermIQ-VLM is VL-MedGuide, a single fine-tuned Visual-Language Large Model organized into two sequential modules that mirror a dermatologist’s “observe → think → diagnose” workflow. In VL-MedGuide, a Multi-modal Concept Perception Module maps a dermatoscopic image $I$ to a set of dermatological concepts $C=\{(v_1,l_1),\dots,(v_k,l_k)\}$, where $v_i\in\{0,1\}$ indicates presence or absence and $l_i$ is a brief linguistic description or justification; an Explainable Disease Reasoning Module then consumes $I$ and $C$ to produce a disease diagnosis $D$ and a human-readable chain-of-thought rationale $R$ (Yu et al., 8 Aug 2025).

Within that work, “DermIQ-VLM” appears as the recommended next-generation system that should carry forward seven design elements: a modular two-stage pipeline, a domain-tuned LVLM backbone, structured prompt templates, chain-of-thought prompts, quantitative and qualitative validation, an explicit performance-interpretability trade-off, and class-specific analysis and robustness testing. The later paper titled “GRPO++: Enhancing Dermatological Reasoning under Low Resource Settings” uses the same name for an implemented dermatology-specialized VLM trained through a three-stage pipeline consisting of GRPO++, supervised fine-tuning, and DPO alignment (Yu et al., 8 Aug 2025, Swapnil et al., 23 Sep 2025).

This dual usage is technically significant. In the first paper, DermIQ-VLM is a design extrapolation from concept-centric explainable diagnosis; in the second, it is a concrete low-resource training methodology. A plausible implication is that the name marks a research trajectory rather than a single fixed architecture.

2. Backbone architecture and systems substrate

The implemented DermIQ-VLM is built on Qwen2-VL backbones, specifically Qwen2-VL-2B and Qwen2.5-VL-3B. The architecture is described as a standard transformer encoder–decoder with cross-modal fusion. Its image encoder is a patch-based ViT that projects to 1,024-dim visual tokens, while the text encoder/decoder uses 1,024-dim token embeddings, learned positional embeddings, and multi-head self- and cross-attention with 32 heads; the 3B model is reported with 40 layers (Swapnil et al., 23 Sep 2025).

Parameter-efficient adaptation is central to the system. LoRA adapters are inserted into attention projections to reduce fine-tuning cost, and 4-bit quantization is used to fit the models on two 15 GB T4 GPUs, with negligible performance loss. The stage-wise integration is explicit: Stage 1 adapts only $q\_\text{proj}$, $k\_\text{proj}$, $C=\{(v_1,l_1),\dots,(v_k,l_k)\}$0, and $C=\{(v_1,l_1),\dots,(v_k,l_k)\}$1 via LoRA, whereas Stages 2 and 3 extend LoRA to feed-forward projections such as $C=\{(v_1,l_1),\dots,(v_k,l_k)\}$2, $C=\{(v_1,l_1),\dots,(v_k,l_k)\}$3, and $C=\{(v_1,l_1),\dots,(v_k,l_k)\}$4 (Swapnil et al., 23 Sep 2025).

VL-MedGuide provides a contrasting architectural emphasis. Rather than foregrounding a particular backbone family, it organizes the system around explicit concept perception and explainable reasoning. Its recommended design insights for a future DermIQ-VLM include a domain-tuned LVLM backbone fine-tuned on paired dermatoscopic images and expert annotations, together with reusable yes/no and descriptive prompt templates for each visual concept (Yu et al., 8 Aug 2025). This suggests that the architectural identity of DermIQ-VLM is partly defined by optimization and prompting strategy, not only by backbone selection.

3. Three-stage optimization pipeline

The implemented training pipeline begins with reasoning-oriented disease recognition via GRPO++. The stated goal is to instill stepwise “differential diagnosis” logic rather than shallow pattern matching. For each image-question prompt $C=\{(v_1,l_1),\dots,(v_k,l_k)\}$5, the policy $C=\{(v_1,l_1),\dots,(v_k,l_k)\}$6 samples $C=\{(v_1,l_1),\dots,(v_k,l_k)\}$7 candidate answers $C=\{(v_1,l_1),\dots,(v_k,l_k)\}$8. A learned reward model $C=\{(v_1,l_1),\dots,(v_k,l_k)\}$9 assigns reward $v_i\in\{0,1\}$0 by checking disease correctness plus clinical-severity penalties, after which the confidence set $v_i\in\{0,1\}$1 is formed with $v_i\in\{0,1\}$2 (Swapnil et al., 23 Sep 2025).

If $v_i\in\{0,1\}$3, the method falls back to standard GRPO by normalizing reward-to-go within the sampled group. If $v_i\in\{0,1\}$4, DermIQ-VLM applies an absolute, confidence-weighted penalty based on the sample log-likelihood:

$v_i\in\{0,1\}$5

where $v_i\in\{0,1\}$6. The optimization target is the clipped PPO-style GRPO++ objective

$v_i\in\{0,1\}$7

with $v_i\in\{0,1\}$8, followed by gradient ascent on $v_i\in\{0,1\}$9 (Swapnil et al., 23 Sep 2025).

Implementation details for Stage 1 are reported as 4-bit quantization plus LoRA with rank $l_i$0, $l_i$1, dropout $l_i$2 on $l_i$3, $l_i$4, $l_i$5, and $l_i$6, trained for 10 epochs ($l_i$7 steps) with learning rate $l_i$8, batch $l_i$9, 4-step gradient accumulation, generation temperature $I$0, and $I$1 (Swapnil et al., 23 Sep 2025).

Stage 2 performs supervised fine-tuning for conversational ability. The objective is to teach the model to produce multi-turn, step-by-step rationales in human-readable form. Each “Image Conversation” record contains an image, a user’s question, and a ground-truth answer structured as <thinking>…detailed dermatological reasoning in stages: color, texture, shape, differential considerations…</thinking> followed by <answer>…final diagnosis and treatment suggestions…</answer>. The loss is standard token-wise cross-entropy,

$I$2

with LoRA expanded to feed-forward projections using rank $I$3, $I$4, dropout $I$5, 4-bit quantization, learning rate $I$6, 2 epochs, batch $I$7, 2-step gradient accumulation, AdamW with weight decay $I$8, a linear scheduler with warmup $I$9, and gradient clipping $C$0 (Swapnil et al., 23 Sep 2025).

Stage 3 uses Direct Preference Optimization alignment through a Knowledge Graph proxy. The grounding KG is a small dermatology knowledge graph of triples such as $C$1symptom, disease, treatment$C$2, built from trusted sources including DermaNet and guidelines. During preference collection, KG-RAG retrieves related triples and prepends them to the prompt to generate a fact-grounded response $C$3, while the base SFT model produces a rejected response $C$4. Preference pairs $C$5 are then optimized with

$C$6

where $C$7. The same quantization and LoRA setup as Stage 2 is used, for 2 epochs at learning rate $C$8 and batch $C$9 (Swapnil et al., 23 Sep 2025).

The paper states that no retrieval is needed at inference once DPO has internalized KG knowledge. This separates the role of KG-RAG as an alignment-time preference generator from the final deployed model (Swapnil et al., 23 Sep 2025).

4. Data regime, supervision format, and evaluation protocol

DermIQ-VLM is explicitly framed for low-resource settings. Stage 1 uses 700 images, 100 per class, from DermNetNZ spanning seven clinically confusable diseases: Actinic Keratosis, Basal Cell Carcinoma, Dermatitis, Melanoma, Psoriasis, Rosacea, and Seborrheic Keratosis. Each sample is paired with a single QA label for disease identification. Stage 2 reuses the same 700 images with multi-turn question–answer data and expert-written chain-of-thought, and Stage 3 generates preference pairs on the fly during training. The held-out test benchmark contains 138 unseen images, approximately 20 per class, for single-shot and majority-voting evaluation (Swapnil et al., 23 Sep 2025).

The annotation schema is tightly controlled. Disease detection uses a single <answer>Disease</answer> tag, while conversation uses the paired <thinking>…</thinking> and <answer>…</answer> format. Evaluation for disease detection reports Precision, Recall, and F1 under both single-shot decoding and 3-way majority vote across $D$0 samples. Conversational quality is assessed on Accuracy, Relevance, and Completeness, rated from 1 to 10 by two LLM judges, Grok and GPT-4. Reward metrics during reinforcement learning use a combined reward consisting of base reward plus a severity matrix (Swapnil et al., 23 Sep 2025).

The evaluative logic of DermIQ-VLM also reflects the earlier VL-MedGuide recommendations. That work explicitly advised balanced accuracy and F1 for both diagnosis and concept detection, together with human-expert Likert studies on clarity and trust, as part of a future DermIQ-VLM validation stack (Yu et al., 8 Aug 2025). In VL-MedGuide itself, disease diagnosis on Derm7pt was evaluated with Balanced Accuracy and F1, where

$D$1

and

$D$2

This suggests continuity between the concept-stage proposal and the later low-resource implementation, even though the datasets and metrics are not identical (Yu et al., 8 Aug 2025).

5. Reported quantitative behavior

For disease detection, the reported single-shot results show large gains over pretrained baselines. On the 2B backbone, Qwen2-VL-2B pretrained achieves F1 $D$3, Qwen2-VL-2B + GRPO++ reaches $D$4, and Qwen2-VL-2B DermIQ-VLM reaches $D$5. On the 3B backbone, Qwen2.5-VL-3B pretrained achieves F1 $D$6, Qwen2.5-VL-3B + GRPO++ reaches $D$7, and Qwen2.5-VL-3B DermIQ-VLM reaches $D$8. The corresponding precision and recall values are also reported: for the final 3B DermIQ-VLM, Precision $D$9 and Recall $R$0 (Swapnil et al., 23 Sep 2025).

Under majority voting, the 3B model reaches F1 $R$1 versus $R$2 for the pretrained model; the paper also states that $R$3 exceeds the GRPO-alone result of $R$4 by $R$5 percentage points. Per-disease breakdowns attribute the largest gains to rare or critical classes, with Melanoma F1 increasing by 27 percentage points and Seborrheic Keratosis F1 increasing by 29 percentage points, while GRPO++ narrows gaps on frequent classes such as Dermatitis, Psoriasis, and Rosacea (Swapnil et al., 23 Sep 2025).

Conversational quality likewise improves across the training stages. The reported evaluation spans four topics—Treatment, Causes, Demographics, and Feature-analysis—and shows average Accuracy, Relevance, and Completeness increasing from pretrained to SFT to full DermIQ-VLM. One concrete example is Qwen2.5-VL-3B Accuracy under Grok, which rises from 6.05 to 7.75 to 8.53, while Completeness rises from 6.10 to 7.10 to 8.45 (Swapnil et al., 23 Sep 2025).

Training dynamics are part of the empirical claim. The GRPO++ reward curves are described as showing smoother upward trends and higher asymptotic rewards than GRPO across both backbones, and the confidence-aware penalty is reported to prevent model collapse on low diversity and high error regimes (Swapnil et al., 23 Sep 2025). Since the evaluation is described as preliminary and conducted on a curated dermatological dataset, these results establish feasibility under constrained conditions rather than a definitive benchmark for general dermatological deployment.

6. Explainability, clinical reasoning, and design trajectory

DermIQ-VLM is not presented as a purely visual classifier. The training objective explicitly includes reasoning-oriented disease recognition, conversational fine-tuning, and factual alignment. The example dialogue in the paper illustrates the intended reasoning style: when asked what features lead to a diagnosis of melanoma rather than basal cell carcinoma, the model’s <thinking> output cites irregular pigmentation, asymmetry, jagged border, and color variegation, then contrasts these with the pearly telangiectatic pattern of BCC; the <answer> concludes that the lesion’s asymmetric, multicolored appearance strongly indicates melanoma and recommends excisional biopsy (Swapnil et al., 23 Sep 2025).

This reasoning style is closely aligned with VL-MedGuide’s explainability paradigm. VL-MedGuide uses handcrafted yes/no and descriptive prompt templates for features such as asymmetry, irregular borders, and more than one color region, then guides diagnosis through a chain-of-thought scaffold: list detected concepts, cite supporting visual evidence, map the features onto known diagnostic criteria such as ABCDE for melanoma, and conclude with the most likely disease. Reported rationales are therefore feature-explicit and criterion-linked, for example connecting asymmetry, multiple colors, irregular borders, and diameter $R$6 mm to melanoma (Yu et al., 8 Aug 2025).

The clinical utility claims are stronger in VL-MedGuide than in the current DermIQ-VLM paper. On Derm7pt, VL-MedGuide reports $R$7 BACC and $R$8 F1 for disease diagnosis, and $R$9 BACC and $q\_\text{proj}$0 F1 for concept detection. Its ablation study shows that removing Concept Perception reduces disease-diagnosis performance to $q\_\text{proj}$1 BACC and $q\_\text{proj}$2 F1, removing CoT Reasoning reduces it to $q\_\text{proj}$3 BACC and $q\_\text{proj}$4 F1, and using an LVLM-Lite backbone yields $q\_\text{proj}$5 BACC and $q\_\text{proj}$6 F1. In human evaluation, three board-certified dermatologists rated 100 test cases on clarity, completeness, and trust using a 5-point Likert scale, yielding rationale clarity $q\_\text{proj}$7, rationale completeness $q\_\text{proj}$8, and perceived trust $q\_\text{proj}$9; physicians reported that the stepwise explanations aligned well with standard clinical reasoning, especially in ambiguous or noisy images where explicit concept descriptions provided a useful audit trail (Yu et al., 8 Aug 2025).

The explicit recommendations carried from VL-MedGuide into the DermIQ-VLM design space remain important for interpretation. These include decoupling explicit concept detection from final diagnosis, maintaining separate yes/no and descriptive prompt templates for each visual concept, enforcing a multi-step reasoning scaffold, accepting a modest inference-time increase of approximately $k\_\text{proj}$0 s per image for transparent rationales with later optimization via distillation, and tracking per-class metrics together with degraded or ambiguous subsets (Yu et al., 8 Aug 2025). A plausible implication is that the presently implemented DermIQ-VLM represents one point in a broader methodological continuum: it operationalizes low-resource reasoning and alignment on quantized Qwen2-VL backbones, while the earlier design program defines a more explicitly modular and concept-centric endpoint for explainable dermatological VLMs.